GET DAILY SIGNALSWhy Is Omada Health (OMDA) Stock Down -17.89% Today?
Key Takeaways
- OMDA shares tumbled roughly 17.89% in intraday trading, sliding to about $15.56 from a prior-session close of $18.95.
- The primary catalyst was a post-earnings "sell the news" reaction: third-quarter results beat estimates, but a soft fourth-quarter outlook and decelerating growth spooked investors.
- Third-quarter revenue rose 34% year over year to $91.3 million, topping consensus, while adjusted EPS of $0.10 also beat expectations, and full-year guidance was raised.
- Secondary drivers included guidance implying fourth-quarter revenue below the third quarter, a slight sequential dip in members, and limited visibility into 2027.
- The move outpaced a modestly lower healthcare sector and a Nasdaq pressured by an AI-led selloff.
- Traders are now watching the January 1, 2027 HCSC expansion launch, 2027 covered-lives disclosures, and the upcoming CEO transition.
- For deeper context, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- Interested in automated strategies? Explore Trending AI Robots to see the top-performing AI trading bots under current conditions.
Opening Summary
Omada Health, Inc. (OMDA), the South San Francisco-based provider of virtual-first care for cardiometabolic and related chronic conditions, saw its shares plunge in Thursday's session following its third-quarter earnings report. The stock was down approximately 17.89%, trading near $15.56 after closing the prior session at $18.95 — a decline of roughly $3.39 per share. The move came even though the company reported better-than-expected results and raised its full-year outlook, as markets focused instead on a softer near-term setup and slowing growth momentum.
Earnings Results and a Raised Outlook
The headline numbers were strong. OMDA reported third-quarter revenue of $91.3 million, up 34% year over year and ahead of the roughly $85.7 million consensus. Adjusted earnings of $0.10 per share topped the $0.09 estimate, GAAP gross margin jumped to 76% from 66% a year earlier, and adjusted EBITDA reached a quarterly record of $12 million. Management raised full-year 2026 revenue guidance to $344 million–$346 million and adjusted EBITDA guidance to $32 million–$34 million, marking its third guidance increase of the year.
Why Investors Sold the News
Despite the beat, the market reaction turned sharply negative. The fourth-quarter outlook implied revenue below the third-quarter level and a slight sequential dip in total members, reflecting normal holiday-season enrollment patterns. Growth is also visibly decelerating: revenue growth cooled to 34% from 43% in the second quarter, and member growth slowed to 36% from 45%. Investors interpreted the softer fourth-quarter guide and the normalizing top-line trajectory as a signal that the exceptional first-half momentum may be fading.
GLP-1 Uncertainty and Cloudier 2027 Visibility
Concerns extended beyond the immediate quarter. Management cited GLP-1 coverage uncertainty and rising healthcare costs as factors extending the selling season deeper into the fourth quarter, and it declined to quantify 2027 covered lives or GLP-1 FlexCare signups. With reports pointing to declining employer GLP-1 coverage heading into 2027, the lack of near-term visibility on next year's pipeline weighed on sentiment, overshadowing the company's record profitability.
Market Context and Trading Activity
The decline was amplified by broader market conditions. The Nasdaq was under pressure following an AI-led selloff, and the healthcare sector traded modestly lower — but OMDA fell far more sharply than peers, indicating a stock-specific reaction to its guidance rather than a purely macro-driven move. Trading activity was elevated, with unusual options volume reported as investors positioned around the earnings event and the company's forward outlook.
What Comes Next for OMDA
Looking ahead, several catalysts will shape OMDA's trajectory. The HCSC fully insured expansion — adding an estimated 1.5 million covered lives across three states — is scheduled to launch January 1, 2027, the same day Wei-Li Shao becomes chief executive with co-founder Sean Duffy moving to executive chairman. Fourth-quarter results will test whether enrollment seasonality and increased R&D and care-team staffing align with the raised full-year range. Risks include the extended selling season, potential pricing pressure from outcome-based performance guarantees, and ongoing uncertainty around employer GLP-1 coverage into 2027.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to monitor automated signals across different market regimes. Explore the Trending AI Robots page to see which strategies are currently leading the field.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OMDA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OMDA turned positive on November 03, 2026. Looking at past instances where OMDA's MACD turned positive, the stock continued to rise in 10 of 10 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +8.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMDA advanced for three days, in 74 of 89 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
OMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 12 of 17 cases where OMDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMDA as a result. In 14 of 20 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for OMDA entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. OMDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.590) is normal, around the industry mean (4.793). P/E Ratio (28.284) is within average values for comparable stocks, (13.685). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.908) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement